FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


GE Capital Provides $6MM Term Loan to Delphinus Medical Technologies

September 11, 2013, 08:01 AM
Filed Under: Medical

GE Capital, Healthcare Financial Services, announced that it is serving as administrative agent and sole lender on a $6 million senior secured multi-draw term loan for Delphinus Medical Technologies, Inc. The company intends to use the financing primarily for clinical and early commercialization efforts.

“GE delivered extremely competitive financing that met our needs directly,” said William Greenway, CEO of Delphinus Medical Technologies. “They also impressed us with their ability to move quickly through the process and close a complex transaction in a short timeframe.”

“Utilizing our industry and finance expertise, we customized financing that aligned with Delphinus’ short and long-term capital needs,” said Anthony Storino, senior managing director, GE Capital, Healthcare Financial Services, Life Sciences. “We will continue to work closely with Delphinus as they move down the path of developing and commercializing their innovative technology.”

Headquartered in Plymouth, MI, Delphinus Medical Technologies is the innovator and developer of the SoftVue whole breast tomography system. The patented technology provides no radiation, no compression, and is not dependent on operator skills. Delphinus has filed with the U.S. Food and Drug Administration for clearance to commercialize the technology.

With in-depth industry knowledge and expertise, GE Capital, Healthcare Financial Services has provided more than $60 billion in financing over ten years to companies in 45 healthcare sectors including senior housing, hospitals, medical offices, outpatient services, pharmaceuticals and medical devices. Our team of professionals creates business and financial solutions tailored to meet the individual needs of our customers.

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.